A Phase 1 Study to Compare the Pharmacokinetics of CAL-101 Capsules to Tablets in Healthy Male Subjects.

A Phase 1 Study to Compare the Pharmacokinetics of CAL-101 Capsules to Tablets in Healthy Male Subjects. - CAL-101 BE study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35094

Enrollment

Registered

2010-02-15

Start date

2010-03-09

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blooddisease leukemia/lymophoma

Interventions

Active substance: CAL-101

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - healthy male volunteers - age between 18 and 65 years (inclusive) - BMI between 18 and 30 kg/m2 - non heavy or average smoker - at screening the state of health satisfies the entry requirements

Exclusion criteria

Exclusion criteria: Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor (500 mL or more) within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Design outcomes

Primary

Measure	Time frame
Safety , Pharmacokinetics	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)